<DOC>
	<DOCNO>NCT00004770</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess efficacy thioctic acid treat single patient mitochondrial myopathy .</brief_summary>
	<brief_title>Pilot Compassionate Use Study Thioctic Acid Treatment Mitochondrial Myopathy</brief_title>
	<detailed_description>PROTOCOL OUTLINE : The patient receive one thioctic acid tablet 3 time day . If patient experience side effect 1 week , 2 tablet administer give 3 time day 3 month compassionate use . The patient follow week 3 , 8 , 12 .</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Mitochondrial Myopathies</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Long stand ophthalmoparesis fatiguable weakness limb Mild ataxia central nervous system involvement History mitochondrial DNA deletion measurable biochemical defect respiratory chain Steady deterioration skeletal muscle mass power 5 year Prior/Concurrent Therapy Previous participation study muscle disease natural history ( CRC Protocol 183A )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>mitochondrial myopathy</keyword>
	<keyword>rare disease</keyword>
</DOC>